-+ 0.00%
-+ 0.00%
-+ 0.00%

NuWays Reiterates Buy on Pentixapharm With EUR 7.20 Price Target

PUBT·11/17/2026 11:44:38
Listen to the news
NuWays Reiterates Buy on Pentixapharm With EUR 7.20 Price Target
  • NuWays reiterated its Buy rating on Pentixapharm Holding on Nov. 17, 2026, with an unchanged 12-month price target of EUR 7.2.
  • PANDA enrollment is now expected in Q1 2027 rather than H2 2026; NuWays still forecasts a US launch in 2030.
  • A commercial partnership expected around summer 2027 could provide upfront funding, reducing reliance on additional equity.
  • The existing convertible bond’s repayment extension to 2030 supports financial flexibility; funding is expected to last into 2028, excluding partnership proceeds.
  • Oncology development offers additional upside outside NuWays’ primary aldosteronism-based valuation, with initial PentixaTher study results expected in December 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27562) on November 17, 2026, and is solely responsible for the information contained therein.